Genmab — Januar 2020
-
Fra før jul: Ang. Teprotumumab: Horizon har fastholdt et peaksale på 750 mio $ i US. Royalty har her været nævnt som 5%. DNB siger 6% og Wainright siger 7%. Iflg DNB vil der i US være 18,765, Europa 43,585 og i Japan 7,690 tilfælde i 2020. Altså mere end dobbelt så mange uden for US. Hvis bare nogen af dem får behandling med tepro vil vi nemt kunne nå 1 mia $, når salget peaker om 5 år. Og hvis vi tager de 7% for gode varer vil det indbringe Genmab op imod ½ mia DKK plus milestones.
-
-
Tak til SB.
-
Det bliver nok en ørkenvandring indtil da.
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/81107_Uge_04___2020.JPG Ser sådan set rimlig fornuftigt ud.
-
Spændende how low we shall go inden det vender?
-
-
Upcoming events – Genmab's route to market,... on TV - https://www.evaluate.com/vantage/articles/events/upcoming-events/upcoming-events-genmabs-route-market-and-late-stage-data
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind